Giorgio Sesti

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.8K citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

John B. Buse, Julio Rosenstock, Giorgio Sesti et al. · The Lancet · 2009 · 1.5K citations

Medicine, Endocrinology, Pharmacology +13

Insulin-Dependent Activation of Endothelial Nitric Oxide Synthase Is Impaired by O-Linked Glycosylation Modification of Signaling Proteins in Human Coronary Endothelial Cells

Massimo Federici, Rossella Menghini, Alessandro Mauriello et al. · Circulation · 2002 · 372 citations · Full text

Life Sciences, Biochemistry, Cell Biology +17

High Glucose Causes Apoptosis in Cultured Human Pancreatic Islets of Langerhans

Massimo Federici, Marta Letizia Hribal, Lucia Perego et al. · Diabetes · 2001 · 329 citations

Life Sciences, Endocrinology, Physiology +13

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial

Olga Vaccaro, Maria Masulli, Antonio Nicolucci et al. · The Lancet Diabetes & Endocrinology · 2017 · 290 citations

Medicine, Endocrinology, Pharmacology +11